Mutant RIT1 cooperates with YAP to drive an EMT-like lung cancer state
The discovery of oncogene addiction in cancer has led to the development of over a dozen FDA-approved biomarker-driven therapies in lung adenocarcinoma. Somatic mutations of the "Ras-like in all tissues" (RIT1) gene are non-canonical driver events in lung cancer, occurring in [~]2% of lung adenocarcinomas in a mutually exclusive fashion with KRAS and EGFR mutations. Patients with RIT1-mutant lung cancer lack targeted therapy treatment options, and a lack of pre-clinical models has hindered the development of therapeutic strategies for RIT1-mutant lung cancer. Here we report a new mouse model of RIT1-driven lung cancer in which the human RIT1M90I variant can be induced in a Cre-regulated manner. We show that autochthonous expression of RIT1M90I in the lung weakly promotes cancer alone or in combination with loss of the p53 tumor suppressor. However, potent synergy between RIT1M90I and inactivation of Nf2 drives an aggressive epithelial-to-mesenchymal (EMT) lung cancer with 100% penetrance and short latency. We show this oncogenic cooperation is driven by synergistic activation of cJUN, a component of the AP-1 complex. Therapeutic inhibition of MEK and YAP/TEAD suppressed RIT1-driven lung cancer in vivo. These data identify YAP/TEAD as an important mediator of RIT1s oncogenic potential and nominate TEAD as an important drug target in RIT1-mutant lung cancer. HIGHLIGHTSO_LIWe report a new RIT1M90I-mutant autochthonous lung tumor model C_LIO_LIThe most common oncogenic variant of RIT1, RIT1M90I, weakly promotes lung tumor development C_LIO_LIRIT1M90I drives the formation of lethal lung tumors in cooperation with p53 and Nf2 tumor suppressor gene loss C_LIO_LIRIT1M90I and YAP cooperatively regulate cJUN expression C_LIO_LITherapeutic MEK and TEAD targeting suppresses RIT1M90I-driven tumorigenesis C_LI